CLOs on the Move

InhibRx

www.inhibrx.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Leah Pollema
General Counsel Profile

Similar Companies

Three Rivers Pharmaceuticals

Three Rivers Pharmaceuticals is a Warrendale, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

INC Research

INC Research is a leading global contract research organization (CRO) providing the full range of Phase I to Phase IV clinical development services for the world's biopharmaceutical and medical device industry. As a therapeutically focused CRO, with a Trusted Process(R) delivery methodology, developing the medicines people need is something we take personally.   Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market to improve world health. We were ranked ""Top CRO to Work With"" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 100 countries.

Aurora Biomed

Aurora Biomed is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Oxyband Technologies

Oxyband Technologies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Juventas Therapeutics

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.